Middle East and Africa Plasma Fractionation Market

MEA Plasma Fractionation Market Size

The MEA Plasma Fractionation Market is projected to grow from USD 2.51 billion in 2025 to USD 2.61 billion in 2026 and reach USD 3.57 billion by 2034, registering a CAGR of 4.02% from 2026 to 2034.

Plasma is the liquid portion of blood that consists of red cells, white cells, and platelets suspended in it and also contains thousands of various proteins and other substances like electrolytes, minerals, hormones, etc., which are necessary for the normal function of the human body. Plasma Fractionation is the fractionation of blood into its constituent parts of red cells, white cells, and platelets, suspended in plasma. The plasma is studied for deficiencies relating to blood disorders and replaced or supplemented with a cure. Maintenance of blood pressure and the regulation of body temperature are among the vital functions of Plasma.

The growth of the Middle East and Africa Plasma Fractionation Market is mainly driven by the increasing occurrence of bleeding and immunity disorders related to blood, the rising use of albumin and immunoglobulins, and the growing aging population.

High costs of plasma products and the side effects of plasma fractionation & plasma exchange are among the factors that hinder the growth of the Middle East and African plasma fractionation market.

This research report on the MEA plasma fractionation market has been segmented and sub-segmented into the following categories:

MEA Plasma Fractionation Market - By Product: 

• Albumin
• Immunoglobulin
• Factor VIII
• Protease Inhibitors

MEA Plasma Fractionation Market - By Application: 

• Neurology
• Hematology
• Rheumatology
• Pulmonology
• Immunology

MEA Plasma Fractionation Market - By End User: 

• Hospitals
• Clinical Laboratories

MEA Plasma Fractionation Market - By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

KEY MARKET PLAYERS:

Some of the companies playing a key role in the MEA plasma fractionation market profiled in the report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).